Scoopfeeds — Intelligent news, curated.
Stifel reiterates Summit Therapeutics stock rating on trial data
business

Stifel reiterates Summit Therapeutics stock rating on trial data

Investing.com · Jun 1, 2026, 12:30 PM · Also reported by 1 other source

Stifel reiterates Summit Therapeutics stock rating on trial data

Read full story on Investing.com → More top stories

Also covered by

Aggregated and edited by the Scoop newsroom. We surface news from Investing.com alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop